Rishi K Wadhera1, Karen E Joynt Maddox2, Yun Wang3, Changyu Shen4, Robert W Yeh5. 1. Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, Massachusetts; Richard and Susan Smith Center for Outcomes Research in Cardiology, Division of Cardiology, Beth Israel Deaconess Medical and Harvard Medical School, Boston, Massachusetts. 2. Washington University School of Medicine, Saint Louis, Missouri. 3. Richard and Susan Smith Center for Outcomes Research in Cardiology, Division of Cardiology, Beth Israel Deaconess Medical and Harvard Medical School, Boston, Massachusetts; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. 4. Richard and Susan Smith Center for Outcomes Research in Cardiology, Division of Cardiology, Beth Israel Deaconess Medical and Harvard Medical School, Boston, Massachusetts. 5. Richard and Susan Smith Center for Outcomes Research in Cardiology, Division of Cardiology, Beth Israel Deaconess Medical and Harvard Medical School, Boston, Massachusetts. Electronic address: ryeh@bidmc.harvard.edu.
Abstract
OBJECTIVES: The purpose of this study was to examine the association of 30-day payments for an episode of heart failure (HF) care at the hospital level with patient outcomes. BACKGROUND: There is increased focus among policymakers on improving value for HF care, given its rising prevalence and associated financial burden in the United States; however, little is known about the relationship between payments and mortality for a 30-day episode of HF care. METHODS: Using Medicare claims data for all fee-for-service beneficiaries hospitalized for HF between July 1, 2011, and June 30, 2014, we examined the association between 30-day Medicare payments at the hospital level (beginning with a hospital admission for HF and across multiple settings following discharge) and patient 30-day mortality using mixed-effect logistic regression models. RESULTS: We included 1,343,792 patients hospitalized for HF across 2,948 hospitals. Mean hospital-level 30-day Medicare payments per beneficiary were $15,423 ± $1,523. Overall observed mortality in the cohort was 11.3%. Higher hospital-level 30-day payments were associated with lower patient mortality after adjustment for patient characteristics (odds ratio per $1,000 increase in payments: 0.961; 95% confidence interval [CI]: 0.954 to 0.967). This relationship was slightly attenuated after accounting for hospital characteristics and HF volume, but remained significant (odds ratio per $1,000 increase: 0.968; 95% CI: 0.962 to 0.975). Additional adjustment for potential mediating factors, including cardiac service capability and post-acute service use, did not significantly affect the relationship. CONCLUSIONS: Higher hospital-level 30-day episode payments were associated with lower patient mortality following a hospitalization for HF. This has implications for policies that incentivize reduction in payments without considering value. Further investigation is needed to understand the mechanisms that underlie this relationship.
OBJECTIVES: The purpose of this study was to examine the association of 30-day payments for an episode of heart failure (HF) care at the hospital level with patient outcomes. BACKGROUND: There is increased focus among policymakers on improving value for HF care, given its rising prevalence and associated financial burden in the United States; however, little is known about the relationship between payments and mortality for a 30-day episode of HF care. METHODS: Using Medicare claims data for all fee-for-service beneficiaries hospitalized for HF between July 1, 2011, and June 30, 2014, we examined the association between 30-day Medicare payments at the hospital level (beginning with a hospital admission for HF and across multiple settings following discharge) and patient 30-day mortality using mixed-effect logistic regression models. RESULTS: We included 1,343,792 patients hospitalized for HF across 2,948 hospitals. Mean hospital-level 30-day Medicare payments per beneficiary were $15,423 ± $1,523. Overall observed mortality in the cohort was 11.3%. Higher hospital-level 30-day payments were associated with lower patient mortality after adjustment for patient characteristics (odds ratio per $1,000 increase in payments: 0.961; 95% confidence interval [CI]: 0.954 to 0.967). This relationship was slightly attenuated after accounting for hospital characteristics and HF volume, but remained significant (odds ratio per $1,000 increase: 0.968; 95% CI: 0.962 to 0.975). Additional adjustment for potential mediating factors, including cardiac service capability and post-acute service use, did not significantly affect the relationship. CONCLUSIONS: Higher hospital-level 30-day episode payments were associated with lower patient mortality following a hospitalization for HF. This has implications for policies that incentivize reduction in payments without considering value. Further investigation is needed to understand the mechanisms that underlie this relationship.
Authors: Corrine Y Jurgens; Sarah Goodlin; Mary Dolansky; Ali Ahmed; Gregg C Fonarow; Rebecca Boxer; Ross Arena; Lenore Blank; Harleah G Buck; Kerry Cranmer; Jerome L Fleg; Rachel J Lampert; Terry A Lennie; JoAnn Lindenfeld; Ileana L Piña; Todd P Semla; Patricia Trebbien; Michael W Rich Journal: Circ Heart Fail Date: 2015-04-08 Impact factor: 8.790
Authors: Larry A Allen; Adrian F Hernandez; Eric D Peterson; Lesley H Curtis; David Dai; Frederick A Masoudi; Deepak L Bhatt; Paul A Heidenreich; Gregg C Fonarow Journal: Circ Heart Fail Date: 2011-03-29 Impact factor: 8.790
Authors: Cynthia Feltner; Christine D Jones; Crystal W Cené; Zhi-Jie Zheng; Carla A Sueta; Emmanuel J L Coker-Schwimmer; Marina Arvanitis; Kathleen N Lohr; Jennifer C Middleton; Daniel E Jonas Journal: Ann Intern Med Date: 2014-06-03 Impact factor: 25.391
Authors: Therese A Stukel; Elliott S Fisher; David A Alter; Astrid Guttmann; Dennis T Ko; Kinwah Fung; Walter P Wodchis; Nancy N Baxter; Craig C Earle; Douglas S Lee Journal: JAMA Date: 2012-03-14 Impact factor: 56.272
Authors: Amber E Barnato; Chung-Chou H Chang; Max H Farrell; Judith R Lave; Mark S Roberts; Derek C Angus Journal: Med Care Date: 2010-02 Impact factor: 2.983
Authors: Jordan B Strom; Yuansong Zhao; Kamil F Faridi; Hector Tamez; Neel M Butala; Linda R Valsdottir; Jeptha Curtis; J Matthew Brennan; Changyu Shen; Mike Boulware; Jeffrey J Popma; Robert W Yeh Journal: Circ Cardiovasc Interv Date: 2019-11-07 Impact factor: 6.546
Authors: Michael Urbich; Gary Globe; Krystallia Pantiri; Marieke Heisen; Craig Bennison; Heidi S Wirtz; Gian Luca Di Tanna Journal: Pharmacoeconomics Date: 2020-11 Impact factor: 4.981